CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. David A. Vallo Senior Protect Manager MedImmune, LLC...

Exhibit 10.36

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.

Xxxxx X. Xxxxx

Senior Protect Manager

MedImmune, LLC

Xxx XxxXxxxxx Xxx

Xxxxxxxxxxxx, XX 00000

XXX

Bellinzona, April 19, 2013

Re: Sub-License and Collaboration Agreement dated as of March 20, 2012 (“Agreement”) between MedImmune LLC (“MedImmune”) and Humabs BioMed SA (“Humabs”)

Dear Xx. Xxxxx,

We hereby notify MedImmune of Humabs’ agreement to extend the scope of the Research Project to work on Klebsiella, which has been elected as the Extra Target in accordance with Section 5.19.2 of the Agreement.

In consideration of the generally increased research costs per FTE at Humabs, we submits to MedImmune the request to increase the amount of Research Funding payments (Section 5.23.1.1. of the Agreement) from [***] of the Research Term.

Thank you for your time and cooperation. We also continue to look forward to a successful collaboration with MedImmune.

Yours sincerely,

/s/ Xxxxxx Xxxxxxxx

Xxxxxx Xxxxxxxx, PhD

President and CEO

Humabs BioMed SA

Xxx Xxxxxxxx 0

XX-0000 Xxxxxxxxxx, Xxxxxxxxxxx

[***]